ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

DaTSCAN 74 MBq/ml solution for injection

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml of solution contains ioflupane (\(^{123}\)I) 74 MBq at reference time (0.07 to 0.13 μg/ml of ioflupane).

Each 2.5 ml single dose vial contains 185 MBq ioflupane (\(^{123}\)I) (specific activity range 2.5 to 4.5 \(\times\) 10\(^{14}\) Bq/mmol) at reference time.

Each 5 ml single dose vial contains 370 MBq ioflupane (\(^{123}\)I) (specific activity range 2.5 to 4.5 \(\times\) 10\(^{14}\) Bq/mmol) at reference time.

Excipient(s) with known effect
This medicinal product contains 39.5 g/l ethanol.
For the full list of excipients see section 6.1.

3. **PHARMACEUTICAL FORM**

Solution for injection.
Clear colourless solution.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

This medicinal product is for diagnostic use only.

DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:

- In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy.

- In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.

4.2 **Posology and method of administration**

Prior to administration appropriate resuscitation equipment should be available.

DaTSCAN should only be used in adult patients referred by physicians experienced in the management of movement disorders and/or dementia. DaTSCAN should only be used by qualified personnel with the appropriate government authorisation for the use and manipulation of radionuclides within a designated clinical setting.
Posology

Clinical efficacy has been demonstrated across the range 111 to 185 MBq. Do not exceed 185 MBq and do not use when the activity is below 110 MBq.

Patients must undergo appropriate thyroid blocking treatment prior to injection to minimise thyroid uptake of radioactive iodine, for example by oral administration of approximately 120 mg potassium iodide 1 to 4 hours prior to injection of DaTSCAN.

Special populations

Renal and hepatic impairment
Formal studies have not been carried out in patients with significant renal or hepatic impairment. No data are available (see section 4.4).

Paediatric population
The safety and efficacy of DaTSCAN in children aged 0 to 18 years has not been established. No data are available.

Method of Administration
For intravenous use.

DaTSCAN should be used without dilution. To minimise the potential for pain at the injection site during administration, a slow intravenous injection (not less than 15 to 20 seconds) via an arm vein is recommended.

Image acquisition
SPECT imaging should take place between three and six hours post-injection. Images should be acquired using a gamma camera fitted with a high-resolution collimator and calibrated using the 159 keV photopeak and a ± 10% energy window. Angular sampling should preferably be not less than 120 views over 360 degrees. For high resolution collimators the radius of rotation should be consistent and set as small as possible (typically 11-15cm). Experimental studies with a striatal phantom, suggest that optimal images are obtained with matrix size and zoom factors selected to give a pixel size of 3.5-4.5 mm for those systems currently in use. A minimum of 500k counts should be collected for optimal images.

4.3 Contraindications

- hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Pregnancy (see section 4.6).

4.4 Special warnings and precautions for use

If hypersensitivity reactions occur, the administration of the medicinal product must be discontinued immediately and, if necessary, intravenous treatment initiated. Resuscitative medicinal products and equipment (e.g. endotracheal tube and ventilator) have to be readily available.

This radiopharmaceutical may be received, used and administered only by authorised persons in designated clinical settings. Its receipt, storage, use, transfer and disposal are subject to the regulations and the appropriate licences of the local competent official organisations.

For each patient, exposure to ionising radiation must be justifiable on the basis of likely benefit. The activity administered must be such that the resulting dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result.
Formal studies have not been carried out in patients with significant renal or hepatic impairment. In the absence of data, DaTSCAN is not recommended in cases of moderate to severe renal or hepatic impairment.

This medicinal product contains 39.5 g/l (5% volume) ethanol (alcohol), up to 197 mg per dose, equivalent to 5 ml beer or 2 ml wine. Harmful for those suffering from alcoholism. To be taken into account in high-risk groups such as patients with liver disease or epilepsy.

**Interpretation of DaTSCAN Images**

DaTSCAN images are interpreted visually, based upon the appearance of the striata. Optimum presentation of the reconstructed images for visual interpretation is transaxial slices parallel to the anterior commissure-posterior commissure (AC-PC) line. Determination of whether an image is normal or abnormal is made by assessing the extent (as indicated by shape) and intensity (in relation to the background) of the striatal signal.

Normal images are characterised by two symmetrical crescent-shaped areas of equal intensity. Abnormal images are either asymmetric or symmetric with unequal or reduced intensity and/or loss of crescent.

As an adjunct, visual interpretation may be assisted by semi-quantitative assessment using CE-marked software, where DaTSCAN uptake in the striatum is compared with uptake in a reference region and ratios are compared against an age adjusted healthy subjects’ database. The evaluation of ratios, such as the left/right striatum DaTSCAN uptake (symmetry) or caudate/putamen uptake, may further help with the image assessment.

The following precautions should be taken when using semi-quantitative methods:
- Semi-quantification should only be used as an adjunct to visual assessment
- Only CE marked software should be used
- Users should be trained in the use of CE marked software by the manufacturer and follow EANM practice guidelines for image acquisition, reconstruction and assessment
- Readers should interpret the scan visually and then perform the semi-quantitative analysis according to manufacturer’s instructions including quality checks for the quantitation process
  - ROI / VOI techniques should be used to compare uptake in the striatum with uptake in a reference region
  - Comparison against an age adjusted healthy subjects database is recommended to account for age-expected decrease in striatal binding
  - The reconstruction and filter settings (including attenuation correction) used can affect the semi-quantitative values. The reconstruction and filter settings recommended by the manufacturer of the CE marked software should be followed and should match those used for semi-quantification of the healthy subjects database.
  - The intensity of the striatal signal as measured by SBR (striatal binding ratio) and asymmetry and caudate to putamen ratio provide objective numerical values corresponding to the visual assessment parameters and can be helpful in difficult to read cases
  - If the semi-quantitative values are inconsistent with the visual interpretation, the scan should be evaluated for appropriate placement of the ROIs / VOIs, correct image orientation and appropriate parameters for image acquisition and attenuation correction should be verified. Some software packages can support these processes to reduce operator-dependent variability
  - Final assessment should always consider both visual appearance and semi-quantitative results

**4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed in humans.
Ioflupane binds to the dopamine transporter. Medicines that bind to the dopamine transporter with high affinity may therefore interfere with DaTSCAN diagnosis. These include amfetamine, benzatropine, bupropion, cocaine, mazindol, methylphenidate, phentermine and sertraline.

Medicines shown during clinical trials not to interfere with DaTSCAN imaging include amantadine, trihexyphenidyl, budipine, levodopa, metoprolol, primidone, propranolol and selegiline. Dopamine agonists and antagonists acting on the postsynaptic dopamine receptors are not expected to interfere with DaTSCAN imaging and can therefore be continued if desired. Medicinal products shown in animal studies not to interfere with DaTSCAN imaging include pergolide.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential
Where it is necessary to administer radioactive medicinal products to women of childbearing potential, information should always be sought about pregnancy. Any woman who has missed a period should be assumed pregnant until proven otherwise. Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving satisfactory imaging. Alternative techniques which do not involve ionising radiation should be considered.

Pregnancy
Animal reproductive toxicity studies have not been performed with this product. Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. Administration of 185 MBq of ioflupane (\(^{123}\)I) results in an absorbed dose to the uterus of 3.0 mGy. DaTSCAN is contraindicated in pregnancy (see section 4.3).

Breastfeeding
It is not known whether ioflupane (\(^{123}\)I) is excreted in human milk. Before administering a radioactive medicinal product to a breast-feeding mother, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breast-feeding and as to whether the most appropriate choice of radiopharmaceutical has been made, bearing in mind the secretion of radioactivity in breast milk. If administration is considered necessary, breast-feeding should be interrupted for 3 days and substituted by formula feeding. During this time, breast milk should be expressed at regular intervals and the expressed feeds should be discarded.

Fertility
No fertility studies have been performed. No data are available.

4.7 Effects on ability to drive and use machines

DaTSCAN has no known influence on the ability to drive and use machines.

4.8 Undesirable effects

The following undesirable effects are recognised for DaTSCAN:

Tabulated summary of adverse reactions
The frequencies of adverse reactions are defined as follows:
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Immune system disorders
Not known: Hypersensitivity
Metabolism and nutrition disorders
Uncommon: Appetite increased

Nervous system disorders
Common: Headache
Uncommon: Dizziness, formication (paraesthesia), dysgeusia

Ear and labyrinth disorders
Uncommon: Vertigo

Skin and subcutaneous tissue disorders
Not known: Erythema, pruritus, rash, urticaria, hyperhidrosis

Respiratory, thoracic and mediastinal disorders
Not known: Dyspnea

Gastrointestinal disorders
Uncommon: Nausea, dry mouth
Not known: Vomiting

Vascular disorders
Not known: Blood pressure decreased

General disorders and administration site conditions
Uncommon: Injection site pain (intense pain or burning sensation following administration into small veins)
Not known: Feeling hot

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 4.63 mSv when the maximal recommended activity of 185 MBq is administered these adverse events are expected to occur with a low probability.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

In cases of overdose of radioactivity, frequent micturition and defaecation should be encouraged in order to minimise radiation dose to the patient. Care should be taken to avoid contamination from the radioactivity eliminated by the patient using such methods.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Diagnostic radiopharmaceutical central nervous system, ATC code: V09AB03.

Due to the low quantities of ioflupane injected, pharmacological effects are not expected following intravenous administration of DaTSCAN at the recommended dosage.
Mechanism of action
Ioflupane is a cocaine analogue. Studies in animals have shown that ioflupane binds with high affinity to the presynaptic dopamine transporter and so radiolabelled ioflupane (\(^{123}\)I) can be used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons. Ioflupane also binds to the serotonin transporter on 5-HT neurons but with lower (approximately 10-fold) binding affinity.

There is no experience in types of tremor other than essential tremor.

Clinical efficacy
Clinical studies in patients with dementia with Lewy bodies

In a pivotal clinical trial including evaluation of 288 subjects with dementia with Lewy bodies (DLB) (144 subjects), Alzheimer’s disease (124 subjects), vascular dementia (9 subjects) or other (11 subjects), the results of an independent, blinded visual assessment of the DaTSCAN images were compared to the clinical diagnosis as determined by physicians experienced in the management and diagnosis of dementias. Clinical categorisation into the respective dementia group was based on a standardised and comprehensive clinical and neuropsychiatric evaluation. The values for the sensitivity of DaTSCAN in determining probable DLB from non-DLB ranged from 75.0% to 80.2% and specificity from 88.6% to 91.4%. The positive predictive value ranged from 78.9% to 84.4% and the negative predictive value from 86.1% to 88.7%. Analyses in which both possible and probable DLB patients were compared with non-DLB dementia patients demonstrated values for the sensitivity of DaTSCAN ranging from 75.0% to 80.2% and specificity from 81.3% to 83.9% when the possible DLB patients were included as non-DLB patients. The sensitivity ranged from 60.6% to 63.4% and specificity from 88.6% to 91.4% when the possible DLB patients were included as DLB patients.

Clinical studies demonstrating adjunctive use of semi-quantitative information for image interpretation

The reliability of using semi-quantitative information as an adjunct to visual inspection was analysed in four clinical studies where sensitivity, specificity or overall accuracy between the two methods of image interpretation were compared. In the four studies (total n=578), CE-marked DaTSCAN semi-quantitation software was used. The differences (i.e., improvements when adding semi-quantitative information to visual inspection) in sensitivity ranged between 0.1% and 5.5%, in specificity between 0.0% and 2.0%, and in overall accuracy between 0.0% and 12.0%.

The biggest of these four studies retrospectively assessed a total of 304 DaTSCAN exams from previously conducted Phase 3 or 4 studies, which included subjects with a clinical diagnosis of PS, non-PS (mainly ET), probable DLB, and non-DLB (mainly AD). Five nuclear medicine physicians who had limited prior experience with DaTSCAN interpretation assessed the images in 2 readings (alone and combined with semi-quantitative data provided by DaTQUANT 4.0 software) at least 1 month apart. These results were compared with the subject’s 1-to 3-year follow-up diagnosis to determine diagnostic accuracy. The improvements in sensitivity and specificity [with 95% confidence intervals] were 0.1% [-6.2%,6.4%] and 2.0% [-3.0%,7.0%]. Also, the results of the combined reading were associated with an increase in reader confidence.

5.2 Pharmacokinetic properties

Distribution
Ioflupane (\(^{123}\)I) is cleared rapidly from the blood after intravenous injection; only 5% of the administered activity remains in whole blood at 5 minutes post-injection.

Organ uptake
Uptake in the brain is rapid, reaching about 7% of injected activity at 10 minutes post-injection and decreasing to 3% after 5 hours. About 30% of the whole brain activity is attributed to striatal uptake.
Elimination
At 48 hours post-injection, approximately 60% of the injected radioactivity is excreted in the urine, with faecal excretion calculated at approximately 14%.

5.3 Preclinical safety data

Non-clinical data for ioflupane reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity.

Studies on reproductive toxicity and to assess the carcinogenic potential of ioflupane have not been performed.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Acetic acid
Sodium acetate
Ethanol
Water for injections

6.2 Incompatibilities
Not applicable

6.3 Shelf-life
2.5 ml vial: 7 hours from the activity reference time stated on the label.
5 ml vial: 20 hours from the activity reference time stated on the label.

6.4 Special precautions for storage
Do not store above 25°C. Do not freeze.

6.5 Nature and contents of container
2.5 or 5 ml solution in a single colourless 10 ml glass vial sealed with a rubber closure and metal overseal.
Pack size of 1.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

General warning
Normal safety precautions for handling radioactive materials should be observed.

Disposal
After use, all materials associated with the preparation and administration of radiopharmaceuticals, including any unused product and its container, should be decontaminated or treated as radioactive waste and disposed of in accordance with the conditions specified by the local competent authority. Contaminated material must be disposed of as radioactive waste via an authorised route.
7. MARKETING AUTHORISATION HOLDER

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands

8. MARKETING AUTHORISATION NUMBERS

EU/1/00/135/001 (2.5 ml)
EU/1/00/135/002 (5 ml)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 27 July 2000
Date of latest renewal: 28 July 2010

10. DATE OF REVISION OF THE TEXT

11 DOSIMETRY

Iodine-123 has a physical half-life of 13.2 hours. It decays emitting gamma radiation with a predominant energy of 159 keV and X-rays of 27 keV.

The estimated absorbed radiation doses to an average adult patient (70 kg) from intravenous injection of ioflupane (\(^{123}\text{I}\)) are listed in the Table below. The values are calculated assuming urinary bladder emptying at 4.8-hour intervals and appropriate thyroid blocking (Iodine-123 is a known Auger electron emitter). Frequent bladder emptying should be encouraged after dosing to minimise radiation exposure.
<table>
<thead>
<tr>
<th>Target Organ</th>
<th>Absorbed radiation dose µGy/MBq</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenals</td>
<td>17.0</td>
</tr>
<tr>
<td>Bone surface</td>
<td>15.0</td>
</tr>
<tr>
<td>Brain</td>
<td>16.0</td>
</tr>
<tr>
<td>Breast</td>
<td>7.3</td>
</tr>
<tr>
<td>Gallbladder wall</td>
<td>44.0</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
</tr>
<tr>
<td>Stomach wall</td>
<td>12.0</td>
</tr>
<tr>
<td>Small intestine wall</td>
<td>26.0</td>
</tr>
<tr>
<td>Colon wall</td>
<td>59.0</td>
</tr>
<tr>
<td>(Upper large intestine wall</td>
<td>57.0</td>
</tr>
<tr>
<td>(Lower large intestine wall</td>
<td>62.0</td>
</tr>
<tr>
<td>Heart wall</td>
<td>32.0</td>
</tr>
<tr>
<td>Kidneys</td>
<td>13.0</td>
</tr>
<tr>
<td>Liver</td>
<td>85.0</td>
</tr>
<tr>
<td>Lungs</td>
<td>42.0</td>
</tr>
<tr>
<td>Muscles</td>
<td>8.9</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>9.4</td>
</tr>
<tr>
<td>Ovaries</td>
<td>18.0</td>
</tr>
<tr>
<td>Pancreas</td>
<td>17.0</td>
</tr>
<tr>
<td>Red marrow</td>
<td>9.3</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>41.0</td>
</tr>
<tr>
<td>Skin</td>
<td>5.2</td>
</tr>
<tr>
<td>Spleen</td>
<td>26.0</td>
</tr>
<tr>
<td>Testes</td>
<td>6.3</td>
</tr>
<tr>
<td>Thymus</td>
<td>9.4</td>
</tr>
<tr>
<td>Thyroid</td>
<td>6.7</td>
</tr>
<tr>
<td>Urinary bladder wall</td>
<td>35.0</td>
</tr>
<tr>
<td>Uterus</td>
<td>14.0</td>
</tr>
<tr>
<td>Remaining organs</td>
<td>10.0</td>
</tr>
<tr>
<td><strong>Effective Dose (µSv/MBq)</strong></td>
<td><strong>25.0</strong></td>
</tr>
</tbody>
</table>


The effective dose (E) resulting from administration of 185 MBq of DaTSCAN injection is 4.63 mSv (per 70 kg individual). The above data are valid in normal pharmacokinetic behaviour. When renal or hepatic function is impaired, the effective dose and the radiation dose delivered to organs might be increased.

12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Any unused medicinal product or waste material should be disposed of in accordance with local requirements. See also section 6.6.

Detailed information on this medicinal product is available on the website of the European Medicines Agency [http://www.ema.europa.eu](http://www.ema.europa.eu)
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

| 5 ml presentation |

---

### 1. NAME OF THE MEDICINAL PRODUCT

DaTSCAN 74 MBq/ml solution for injection. Ioflupane \(^{123}\text{I}\)

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml of solution contains ioflupane \(^{123}\text{I}\) 74 MBq at reference time (0.07 to 0.13 μg/ml of ioflupane).

### 3. LIST OF EXCIPIENTS

- 5% ethanol (see leaflet for further information)
- Acetic acid, sodium acetate, water for injections

### 4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

| 1 vial |

---

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intravenous use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

![Radioactive]

### 8. EXPIRY DATE

EXP: 20 h post-ref.

Ref.: 370 MBq/5 ml at 2300 CET on DD/MM/YYYY

### 9. SPECIAL STORAGE CONDITIONS

- Do not store above 25°C.
- Do not freeze.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Handling and disposal – see package leaflet.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/00/135/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

Not applicable

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

Not applicable
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

5 ml presentation

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

DaTSCAN 74 MBq/ml solution for injection.
Ioflupane (\(^{123}\text{I}\))
Intravenous use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP: 20 h post-ref.
Ref.: 370 MBq/5 ml ioflupane (\(^{123}\text{I}\)) at 2300 CET on DD/MM/YYYY.

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

5 ml

6. OTHER

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

2.5 ml presentation

1. NAME OF THE MEDICINAL PRODUCT

DaTSCAN 74 MBq/ml solution for injection
Ioflupane (\(^{123}\)I)

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml of solution contains ioflupane (\(^{123}\)I) 74 MBq at reference time (0.07 to 0.13 μg/ml of ioflupane).

3. LIST OF EXCIPIENTS

5% ethanol (see leaflet for further information), acetic acid, sodium acetate, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intravenous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP: 7 h post-ref.
Ref.: 185 MBq/2.5 ml at 1200 CET on DD/MM/YYYY

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Do not freeze.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Handling and disposal – see package leaflet.

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/00/135/001

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS FOR USE**

16. **INFORMATION IN BRAILLE**

Justification for not including Braille accepted

17. **UNIQUE IDENTIFIER – 2D BARCODE**

Not applicable

18. **UNIQUE IDENTIFIER – HUMAN READABLE DATA**

Not applicable
1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

DaTSCAN 74 MBq/ml solution for injection
Ioflupane (\(^{123}\)I)
Intravenous use

2. **METHOD OF ADMINISTRATION**

3. **EXPIRY DATE**

EXP: 7 h post-ref.
Ref.: 185 MBq/2.5 ml ioflupane (\(^{123}\)I) at 1200 CET on DD/MM/YYYY

4. **BATCH NUMBER**

Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

2.5 ml

6. **OTHER**

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands
B. PACKAGE LEAFLET
Package leaflet: Information for the user

DaTSCAN 74 MBq/ml solution for injection
Ioflupane (I\(^{123}\))

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

– Keep this leaflet. You may need to read it again.
– If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
– If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What DaTSCAN is and what it is used for
2. What you need to know before DaTSCAN is used
3. How DaTSCAN is used
4. Possible side effects
5. How DaTSCAN is stored
6. Contents of the pack and other information

1. What DaTSCAN is and what it is used for

DaTSCAN contains the active substance ioflupane (I\(^{123}\)) which is used to help identify (diagnose) conditions in the brain. It belongs to a group of medicines called “radiopharmaceuticals”, which contain a small amount of radioactivity.

- When a radiopharmaceutical is injected, it collects in a specific organ or area of the body for a short time.
- Because it contains a small amount of radioactivity it can be detected from outside the body using special cameras.
- A picture, known as a scan, can be taken. This scan will show exactly where the radioactivity is inside the organ and the body. This can give the doctor valuable information about how that organ is working.

When DaTSCAN is injected into an adult, it is carried around the body in the blood. It collects in a small area of your brain. Changes in this area of the brain occur in:

- Parkinsonism (including Parkinson’s disease) and
dementia with Lewy bodies.

A scan will give your doctor information about any changes in this area of your brain. Your doctor may feel that the scan would help in finding out more about your condition and deciding on possible treatment.

When DaTSCAN is used, you are exposed to small amounts of radioactivity. This exposure is less than in some types of X-ray investigation. Your doctor and the nuclear medicine doctor have considered that the clinical benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed to these small amounts of radiation.

This medicine is used for diagnostic use only. It is used only to identify illness.
2. **What you need to know before DaTSCAN is used**

**DaTSCAN must not be used**
- if you are allergic to ioflupane or any of the other ingredients of this medicine (listed in section 6).
- if you are pregnant

**Warnings and precautions**
Talk to your nuclear medicine doctor before using DaTSCAN if you have a moderate or severe problem with your kidneys or liver.

**Children and adolescents**
DaTSCAN is not recommended for children aged 0 to 18 years

**Other medicines and DaTSCAN**
Tell your nuclear medicine doctor if you are taking or have recently taken any other medicines. Some medicines or substances can affect the way that DaTSCAN works. These include:
- buproprion (used to treat depression (sadness))
- benztropine (used to treat Parkinson’s disease)
- mazindol (reduces appetite, as a means to treat obesity)
- sertraline (used to treat depression (sadness))
- methylphenidate (used to treat hyperactivity in children and narcolepsy (excessive sleepiness))
- phentermine (reduces appetite, as a means to treat obesity)
- amphetamine (used to treat hyperactivity in children and narcolepsy (excessive sleepiness); also a drug of abuse)
- cocaine (sometimes used as an anaesthetic for nose surgery; also a drug of abuse)

Some medicines may reduce the quality of the picture obtained. The doctor may ask you to stop taking them for a short time before you receive DaTSCAN.

**Pregnancy and breast-feeding**
Do not use DaTSCAN if you are pregnant or think you may possibly be pregnant. This is because the child may receive some of the radioactivity. Tell your nuclear medicine doctor if you think you might be pregnant. Alternative techniques which do not involve radioactivity should be considered.

If you are breast-feeding, your nuclear medicine doctor may delay the use of DaTSCAN, or ask you to stop breast-feeding. It is not known whether ioflupane (123I) is passed into breast milk.

- You should not breast-feed your child for 3 days after DaTSCAN is given.
- Instead use formula feed for your child. Express your breast milk regularly and throw away any breast milk you have expressed.
- You will need to continue to do this for 3 days, until the radioactivity is no longer in your body.

**Driving and using machines**
DaTSCAN has no known influence on the ability to drive and use machines.

**DaTSCAN contains** alcohol (ethanol) 5 % by volume. Each dose contains up to 197 mg alcohol. This is about the same as 5 ml beer, or 2 ml wine. This is harmful for those suffering from alcoholism and needs to be taken into account in pregnant or breastfeeding women, children and high risk groups such as patients with liver disease or epilepsy. Tell your doctor if any of these apply to you.

3. **How DaTSCAN is used**

There are strict laws on the use, handling and disposal of radioactivity. DaTSCAN will always be used in a hospital or a similar place. It will only be handled and given to you by people who are trained and qualified to use it safely. They should tell you anything you need to do for the safe use of this medicine.
Your nuclear medicine doctor will decide the dose that is best for you.

Before you receive DaTSCAN, your nuclear medicine doctor will ask you to take some tablets or liquid that contain iodine. These stop the radioactivity building-up in your thyroid gland. It is important that you take the tablets or liquid as the doctor tells you.

DaTSCAN is given to you as an injection, usually into a vein in your arm. The recommended radioactivity given by injection is between 111 to 185 MBq (megabequerel or MBq is a unit used to measure radioactivity). A single injection is enough. The camera pictures are usually taken 3 to 6 hours after the injection of DaTSCAN.

If you are given more DaTSCAN than you should
Since DaTSCAN is given by a doctor under controlled conditions, it is unlikely that you will get an overdose. Your nuclear medicine doctor will suggest that you drink plenty of fluids to help the body get rid of the medicine. You will need to be careful with the water (urine) that you pass - your doctor will tell you what to do. This is normal practice with medicines like DaTSCAN. Any ioflupane (123I) which remains in your body will naturally lose its radioactivity.

If you have any further questions on the use of this medicine, ask your nuclear medicine doctor who supervises the procedure.

4. Possible side effects

Like all medicines, DaTSCAN can cause side effects, although not everybody gets them. The frequency of side effects is:

Common: may affect up to 1 in 10 people
- Headache

Uncommon: may affect up to 1 in 100 people
- Increased appetite
- Dizziness
- Taste disturbance
- Nausea
- Dry mouth
- Vertigo
- A brief irritating feeling similar to ants crawling over your skin (formication)
- Intense pain (or burning sensation) at the injection site. This has been reported among patients receiving DaTSCAN into a small vein.

Not known: frequency cannot be estimated from the available data.
- Hypersensitivity (allergic)
- Shortness of breath
- Redness of the skin
- Itching
- Rash
- Hives (urticaria)
- Excessive sweating
- Vomiting
- Low blood pressure
- Feeling hot

The amount of radioactivity in the body from DaTSCAN is very small. It will be passed out of the body in a few days without need for you to take special precautions.
**Reporting of side effects**
If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How DaTSCAN is stored**

You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.

The following information is intended for the specialist only:
- Keep this medicine out of the sight and reach of children.
- Do not store above 25°C.
- Do not freeze.

Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month. Hospital staff will ensure that the product is stored and thrown away correctly and not used after the expiry date stated on the label.

6. **Contents of the pack and other information**

**What DaTSCAN contains**
- The active substance is ioflupane (\(^{123}\)I). Each ml of solution contains ioflupane (\(^{123}\)I) 74 MBq at reference time (0.07 to 0.13 μg/ml of ioflupane).
- The other ingredients are acetic acid, sodium acetate, ethanol and water for injections.

**What DaTSCAN looks like and contents of the pack**
DaTSCAN is a 2.5 or 5 ml colourless solution for injection, supplied in a single colourless 10 ml glass vial sealed with a rubber closure and metal overseal.

**Marketing Authorisation Holder and Manufacturer**

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
GE Healthcare
Tél/Tel: +32 (0) 2 719 7410

**България**
GE Healthcare Bulgaria EOOD
Тел: +359 2 9712040

**Lietuva**
VitaFARMA UAB
Tel.: +370 37 225322

**Luxembourg/Luxemburg**
GE Healthcare
België/Belgique/Belgien
Tél/Tel: +32 (0) 2 719 7410
<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Česká republika</td>
<td>M.G.P. spol. s r.o.</td>
<td>+420 577 212 140</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Radizone Diagnost-X Kft.</td>
<td>+36 1 787-5720</td>
</tr>
<tr>
<td>Danmark</td>
<td>GE Healthcare A/S</td>
<td>+45 70 2222 03</td>
</tr>
<tr>
<td>Malta</td>
<td>Pharma-Cos Ltd.</td>
<td>+ 356 22266300</td>
</tr>
<tr>
<td>Deutschland</td>
<td>GE Healthcare Buchler GmbH &amp; Co. KG</td>
<td>+49 (0) 5 307 93 00</td>
</tr>
<tr>
<td>Nederland</td>
<td>GE Healthcare B.V.</td>
<td>+31 (0) 40 299 10 00</td>
</tr>
<tr>
<td>Eesti</td>
<td>GE Healthcare Estonia OÜ</td>
<td>+372 6260 061</td>
</tr>
<tr>
<td>Norge</td>
<td>GE Healthcare AS</td>
<td>+47 23 18 50 50</td>
</tr>
<tr>
<td>Espaňa</td>
<td>GE Healthcare Bio-Sciences, S.A.U</td>
<td>+34 91 663 25 00</td>
</tr>
<tr>
<td>Österreich</td>
<td>GE Healthcare Handels GmbH</td>
<td>+43 (0) 1 97272-0</td>
</tr>
<tr>
<td>España</td>
<td>GE Healthcare SAS</td>
<td>+33 1 34 49 54 54</td>
</tr>
<tr>
<td>Polska</td>
<td>GE Medical Systems Polska Sp. z o.o.</td>
<td>+4822 330 83 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>BIOVIT d.o.o.</td>
<td>+ 385 42 260 001</td>
</tr>
<tr>
<td>Portugal</td>
<td>Satis – GE Healthcare</td>
<td>+351 214251352</td>
</tr>
<tr>
<td>Ireland</td>
<td>GE Healthcare Limited UK</td>
<td>+44 (0) 1494 54 5306</td>
</tr>
<tr>
<td>România</td>
<td>MagnaPharm Marketing &amp; Sales Romania S.R.L.</td>
<td>+ 40 372 502 221</td>
</tr>
<tr>
<td>Ísland</td>
<td>Icepharma</td>
<td>+ 354 540 8000</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Biomedis M.B. trgovina d.o.o.</td>
<td>+386 2 4716300</td>
</tr>
<tr>
<td>Ireland</td>
<td>GE Healthcare S.r.l.</td>
<td>+39 02 26001 111</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>MGP, spol. s r. o.</td>
<td>+421 2 5465 4841</td>
</tr>
<tr>
<td>Italia</td>
<td>GE Healthcare S.r.l.</td>
<td>+391 34 99 994 830</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Oy GE Healthcare Bio-Sciences Ab</td>
<td>+358 10 39411</td>
</tr>
<tr>
<td>Kύπρος</td>
<td>Phadisco Ltd</td>
<td>+357 22 715000</td>
</tr>
<tr>
<td>Sverige</td>
<td>GE Healthcare AB</td>
<td>+46 (0) 8 559 504 00</td>
</tr>
<tr>
<td>Latvija</td>
<td>General Electric International Inc.</td>
<td>+371 6780 7086</td>
</tr>
<tr>
<td>United Kingdom (Northern Ireland)</td>
<td>GE Healthcare Limited</td>
<td>+44(0)1494 54 5306</td>
</tr>
</tbody>
</table>
This leaflet was last revised in \{MM/YYYY\}

Detailed information on this medicine is available on the European Medicines Agency web site; http://www.ema.europa.eu.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.